DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies ...

Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...

The combination of Opdivo and Yervoy is supported by updated results as a standard of care for MSI-H or dMMR metastatic colorectal cancer. Opdivo (nivolumab ... Patients with histologically confirmed ...

CheckMate -8HW enrolled patients with colorectal cancer whose tumors were characterized as microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic.

Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer. ScienceDaily . Retrieved February 18, 2025 from www.sciencedaily.com ...

We need a much larger study." In her introductory comments, Geng agreed with Kunz's assessment that unresectable locally advanced/metastatic G/GEJ cancer has a poor prognosis, and chemotherapy is ...

The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior ...

In BMS’ case, the company’s dual immunotherapy of Opdivo and Yervoy showed it could work better than Opdivo alone in patients with certain metastatic colorectal cancer. The combo lowered the ...